E-POSTER DETAIL | 11th Asia Pacific Tele Ophthalmology Society Symposium

Title
Alterations of the Vitreoretinal Interface in Retinal Vein Occlusion (RVO) Patients Post-Anti-VEGF Treatment

Authors
Zhengwei Zhang

Presenting
Zhengwei Zhang

PURPOSE:
To investigate the characteristics of vitreoretinal interface (VRI) changes and factors influencing therapeutic outcomes in retinal vein occlusion (RVO) patients undergoing anti-vascular endothelial growth factor (VEGF) therapy.

METHODS:
This retrospective cohort study enrolled 203 patients with retinal vein occlusion (RVO) who received anti-VEGF treatment. Optical coherence tomography (OCT) was utilized to assess changes in the VRI pre- and post-treatment, including posterior vitreous detachment (PVD) status and the incidence of epiretinal membrane (ERM).

RESULTS:
A total of 190 patients with RVO were included in the final analysis. The incidence of ERM was significantly higher in the CRVO group (62.7%; 47/75) compared to the BRVO group (33.9%; 39/115) (P < 0.001). Multivariate logistic regression identified the CRVO subtype, baseline PVD status (both complete and incomplete). The incidence of ERM was significantly higher in patients who progressed from incomplete to complete PVD (68.0%) compared to those without PVD progression (23.5%). Patients with baseline complete PVD also exhibited a significantly elevated ERM incidence (51.8%) (P < 0.001). Among the four anti-VEGF agents administered (conbercept, ranibizumab, aflibercept, and faricimab), there were no significant differences regarding the incidence of ERM (all Ps > 0.05).

RESULTS:

A total of 190 patients with RVO were included in the final analysis. The incidence of ERM was significantly higher in the CRVO group (62.7%; 47/75) compared to the BRVO group (33.9%; 39/115) (P < 0.001). Multivariate logistic regression identified the CRVO subtype, baseline PVD status (both complete and incomplete). The incidence of ERM was significantly higher in patients who progressed from incomplete to complete PVD (68.0%) compared to those without PVD progression (23.5%). Patients with baseline complete PVD also exhibited a significantly elevated ERM incidence (51.8%) (P < 0.001). Among the four anti-VEGF agents administered (conbercept, ranibizumab, aflibercept, and faricimab), there were no significant differences regarding the incidence of ERM (all Ps > 0.05).

CONCLUSIONS:
Following anti-VEGF therapy for RVO, the development of ERM is closely associated with the CRVO subtype, baseline PVD status, and the total number of injections. PVD progression—particularly the transition from incomplete to complete PVD—significantly increases the risk of ERM formation. The specific type of anti-VEGF agent does not significantly affect ERM incidence.